MOMO'S BREAKOUT BOARD

[dirkv]

QUINCE THERAPEUTICS (QNCX): 1.04 - 8.77%

52w: 1.04 - 91.76

Quince Therapeutics, Inc., formerly Cortexyme, Inc., is a biopharmaceutical company. The Company is focused on advancing precision therapeutics targeting debilitating and rare diseases. The Company has discovered a bone-targeting drug platform capable of delivering small molecules, peptides, or large molecules directly to the site of broad bone fractures and disease designed to promote more healing with fewer off-target safety concerns. The Company’s lead compound, NOV004, is an anabolic peptide engineered to target and concentrate at the bone fracture site. Its discovery pipeline is focused on expanding across multiple skeletal therapeutic indications, including osteogenesis imperfecta, fractures, spinal fusion, and other severe diseases of bone such as cancer or infection. The Company's pipeline also includes legacy neuroscience and antiviral programs available for out-licensing, which include COR588, COR388, COR852 and COR803.

Strong cash position of approximately $105 million provides operating runway into the second half of 2025
Shares Outstanding 36.1M
Float 24.88M
Total Cash Per Share (mrq) 2.88
Total Debt (mrq) 524k